Israeli Researchers Innovate Schizophrenia Treatment with DBS Breakthrough

Israeli scientists have achieved a significant advancement in the treatment of schizophrenia, demonstrating immediate improvements in brain function during a recent trial. Conducted at the Rambam Health Care Campus in Haifa, the study involved two monkeys that underwent a unique treatment combining hallucinogens and electrical stimulation through a technique known as Deep Brain Stimulation (DBS).

The research team aimed to address the disconnection within the brain that is often a critical factor in schizophrenia. According to Nir Asch, a lead researcher at the medical center’s psychiatric department, the brain functions as a “prediction machine.” It creates models based on sensory input to navigate the world. In individuals with schizophrenia, this process falters, leading to a disconnect between their internal model and external realities. “They are kind of stuck in their own model,” Asch explained, noting that despite receiving sensory input, these individuals struggle to interpret it appropriately.

During the trial, the monkeys were administered hallucinogens that induced chaotic and dissociated behaviors, mimicking symptoms seen in those suffering from schizophrenia. Following this, the team applied DBS using electrical impulses. Remarkably, the results showed an immediate restoration of normal brain function, effectively eliminating the disconnect. “The cognitive inflexibility was cured,” Asch stated, adding that the monkeys exhibited behavior akin to their healthy state, with significantly reduced chaos.

Following the success of this study, the research team is eager to progress to human trials. Asch remarked, “Because the study was successfully performed on non-human primates, whose brains are remarkably similar to those of humans, we’re already meeting to discuss the best way to move forward.” This transition marks a hopeful step towards developing effective treatments for a condition that affects millions worldwide.

In addition to his research role, Asch practices as a doctor, which fuels his motivation to advance this treatment. Witnessing the challenges faced by patients and their families deeply impacts him. “It can be very frustrating as a doctor when we don’t have great treatments,” he noted. “If we can add more tools that are effective and pave the way to recovery, then it would be so wonderful.”

The implications of this research are vast, promising new avenues for those living with schizophrenia. As the team prepares to embark on the next phase of their research, the scientific community remains hopeful that the innovative applications of DBS may lead to transformative changes in mental health treatment.